NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 08/07/2026 12:12
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization250.48 mln
Float268 mln
Earnings Date10/29/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-3.37
Reliable
Relative Strength
3
/ 100
Severely lagging
Debt / Equity
2.20
Very high leverage
ROE
-95.19
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Akebia Therapeutics is a Massachusetts-based medical company founded in 2007 that develops and sells treatments for people living with kidney disease. Its two approved medicines help patients manage anemia and high phosphorus levels associated with chronic kidney disease, while two additional drugs are currently being tested in clinical trials for conditions including kidney injury following heart surgery and an eye disorder affecting premature newborns. The company markets its products across multiple regions through licensing partnerships with pharmaceutical firms in Japan, Asia, and other territories.
